Equities Analysts Offer Predictions for Hill-Rom Holdings, Inc.’s FY2021 Earnings (NYSE:HRC)

Equities Analysts Offer Predictions for Hill-Rom Holdings, Inc.’s FY2021 Earnings (NYSE:HRC)

Hill-Rom Holdings, Inc. (NYSE:HRC) – Equities researchers at KeyCorp issued their FY2021 earnings per share estimates for shares of Hill-Rom in a research note issued to investors on Sunday, August 4th. KeyCorp analyst M. Mishan forecasts that the medical technology company will post earnings per share of $6.25 for the year. KeyCorp currently has a “Overweight” rating and a $125.00 price objective on the stock.

A number of other equities analysts have also recently issued reports on HRC. Needham & Company LLC reiterated a “buy” rating and issued a $125.00 price objective on shares of Hill-Rom in a report on Tuesday. Zacks Investment Research upgraded Hill-Rom from a “hold” rating to a “buy” rating and set a $103.00 price objective for the company in a report on Thursday, June 6th. Barclays upped their price objective on Hill-Rom from $108.00 to $116.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $112.43.

HRC opened at $103.58 on Wednesday. The business has a 50-day moving average price of $105.29. Hill-Rom has a 12-month low of $81.82 and a 12-month high of $109.18. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.51 and a quick ratio of 1.14. The stock has a market cap of $6.94 billion, a PE ratio of 21.81, a P/E/G ratio of 1.80 and a beta of 0.90.

Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, August 2nd. The medical technology company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.02. Hill-Rom had a return on equity of 21.26% and a net margin of 7.45%. The firm had revenue of $726.80 million during the quarter, compared to analysts’ expectations of $718.08 million. During the same period in the prior year, the business earned $1.15 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Friday, September 20th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date of this dividend is Thursday, September 19th. Hill-Rom’s payout ratio is currently 17.68%.

A number of hedge funds have recently modified their holdings of the stock. Avitas Wealth Management LLC boosted its holdings in Hill-Rom by 0.5% during the 1st quarter. Avitas Wealth Management LLC now owns 22,829 shares of the medical technology company’s stock valued at $2,417,000 after acquiring an additional 119 shares during the period. US Bancorp DE boosted its holdings in Hill-Rom by 3.2% during the 1st quarter. US Bancorp DE now owns 5,068 shares of the medical technology company’s stock valued at $536,000 after acquiring an additional 155 shares during the period. Private Trust Co. NA boosted its holdings in Hill-Rom by 3.4% during the 2nd quarter. Private Trust Co. NA now owns 5,345 shares of the medical technology company’s stock valued at $559,000 after acquiring an additional 175 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Hill-Rom by 5.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,058 shares of the medical technology company’s stock valued at $425,000 after acquiring an additional 200 shares during the period. Finally, Johanson Financial Advisors Inc. boosted its holdings in Hill-Rom by 8.3% during the 1st quarter. Johanson Financial Advisors Inc. now owns 2,639 shares of the medical technology company’s stock valued at $280,000 after acquiring an additional 202 shares during the period. Institutional investors own 81.52% of the company’s stock.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Share:
Scroll Up